Floor J. Backes, MD, discusses the results from a phase I trial investigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.
Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discussesthe results from a phase I trialinvestigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.
The primary goal of the study was to find a recommended phase II dose. The trial established an 80 mg weekly of paclitaxel and a daily dose of lenvatinib at 60 mg, says Backes. The combination appeared safe and tolerable in these patients.
Holloway Discusses the Rationale for PARP Inhibition in Advanced Ovarian Cancer
November 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Robert Holloway, MD, explored the state of PARP inhibitors for patients with advanced ovarian cancer including the PRIMA trial of niraparib.
Read More